Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alicia Haslauer

Physician Assistant Metairie, LA Physician Assistant

NPI 1174832612 CMS profile 10494759

111 Veterans Memorial Blvd, Suite 406, Metairie, LA 70005

Open in the dashboard

General payments

$14,296

412 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alicia Haslauer of Metairie, LA is reported in the CMS Open Payments database as having received $14,296 across 412 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,932 104
2024 General $1,589 75
2023 General $1,928 87
2022 General $1,604 79
2021 General $1,243 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alicia Haslauer
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Alicia Haslauer were reported at $7,932. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Alicia Haslauer Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,243 $132 $37–$438 $132
2022 $1,604 $155 $48–$522 $149
2023 $1,928 $167 $52–$557 $160
2024 $1,589 $178 $55–$600 $164
2025 $7,932 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Galderma Laboratories, L.P. $6,232 28 payments
  2. Genzyme Corporation $1,860 76 payments
  3. AbbVie, Inc. $1,178 76 payments
  4. Regeneron Healthcare Solutions, Inc. $843 34 payments
  5. Lilly USA, LLC $824 45 payments
  6. Novartis Pharmaceuticals Corporation $534 33 payments
  7. Incyte Corporation $350 15 payments
  8. Janssen Biotech, Inc. $323 10 payments
  9. UCB, Inc. $310 14 payments
  10. Pfizer Inc. $302 19 payments
  11. Other $1,541 62 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,432 400 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,100 4 payments
  3. Travel and Lodging $474 3 payments
  4. Education $290 5 payments
Products named General payments · program years 2021–2025
  1. NEMLUVIO $6,153 23 payments
  2. DUPIXENT Immunology $2,314 91 payments
  3. DUPIXENT Inflammation And Immunology $674 28 payments
  4. RINVOQ $616 35 payments
  5. TALTZ $613 36 payments
  6. OPZELURA $350 15 payments
  7. TREMFYA $323 10 payments
  8. EBGLYSS $317 14 payments
  9. Otezla $293 14 payments
  10. COSENTYX $280 21 payments
  11. Other $3,166 166 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

277

Median for Physician Assistant: 241

Drug cost

$88,474

Median for Physician Assistant: $4,110

Branded share of claims

9.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Taltz Autoinjector Ixekizumab Brand 11 $74,855
Tacrolimus Generic 25 $4,265
Clobetasol Propionate Generic 49 $2,702
Calcipotriene Generic 11 $1,477
Ketoconazole Generic 78 $1,301
Desonide Generic 15 $1,241
Fluocinolone Acetonide Fluocinolone/Shower Cap Brand 16 $1,144
Fluorouracil Generic 11 $742
Triamcinolone Acetonide Generic 34 $444
Doxycycline Monohydrate Generic 11 $211

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$7,790

Medicare's payments for the services billed

Medicare patients

58

Average age 70

Services billed

196

35 women, 23 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 50%
Depression 26%
Diabetes 24%
Chronic kidney disease 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $295
  • Regeneron Healthcare Solutions, Inc. $143
  • SANOFI-AVENTIS U.S. LLC $72
$511 — —
Bimzelx
  • UCB, Inc. $156
$156 — —
RINVOQ
  • AbbVie, Inc. $145
$145 — —
TALTZ
  • Lilly USA, LLC $111
$111 11 —
SKYRIZI
  • AbbVie, Inc. $108
$108 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

412 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record